BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting
Elin Trampe describes the unmet need the company believes exists for ED today, the history of their drug and how it was invented in Sweden's Uppsala University, and uplising to the First North Growth Market this week.
Brought to you by